“The most incomprehensible thing about the world is that it is at all comprehensible”
something about us
73100 is a Portuguese biotechnology SME dedicated to the development of new biotechnology based products and processes with applications in the pharmaceutical and cosmetics industry.
It was founded in 2006 and its portfolio has been growing since. Its mission is to develop technology from the early idea stage to the pilot demonstration stage, and from that point on to commercialize the technology to industrial partners or develop industrial projects together with industrial partners.
It now has a considerable Intellectual Property portfolio of diverse types of R&D technologies with the objective of bringing the result of their R&D projects to products and services that can be useful to users in the market.
73100 develops its projects using platforms in Universities and Research Institutes in Portugal. The development teams work on projects contracted with 73100, in a natural R&D environment, under the scientifically leadership of specialized selected Professors and 73100 direct coordination.
We undertake the development and licensing of patents and proceed to the commercialization or production scale either through the direct development or by sale or spin-off of projects.
something about our subsidiaries
Pharma73 is a Portuguese start-up, dedicated to the development, production and commercialization of a new generation of enhanced performance High Functionality Excipients (HFE’s). Pharma73 has developed a proprietary fermentation technology which enables them to produce natural biopolymer products.
Since 2011 and up to now, Pharma73 has engaged on the Proof-of-concept stage of its biopolymer production technology platform and is planning market entry of it’s first products in 2017
ExtremoChem is a Portuguese company devoted to the development and commercialization of novel small synthetic molecules for the stabilization of biologicals.
The technology is inspired in nature’s ability to sustain life under extreme conditions.
New molecules have been synthesised and developed for use as new excipients for the stabilization of proteins. These molecules are analogues of the molecules found in nature, with improved stabilization properties.